South Delhi Pharma, New Delhi, India
ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use.
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email email@example.com to discuss.
ONTRUZANT is a prescription medicine. ONTRUZANT is used to treat breast cancer
INDICATIONS AND USAGE
Ontruzant is a HER2/neu receptor antagonist indicated for:
• The treatment of HER2-overexpressing breast cancer.
• The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.
DOSAGE FORMS & STRENGTHS
For Injection: 150 mg lyophilized powder in a single-dose vial for reconstitution.
• For Injection: 420 mg lyophilized powder in a multiple-dose vial for reconstitution.
Manufactured By: Merck Sharp & Dohme Corp.
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “ONTRUZANT (trastuzumab-dttb) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Trastuzumab-dttb was first approved as a 150 mg single-dose vial by the FDA in January 2019 across all eligible indications, mainly adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.
Trastuzumab-dttb is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer, including:
• As a part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel.
• With docetaxel and carboplatin.
• As a single agent following multi-modality anthracycline-based therapy.
In addition, trastuzumab-dttb is indicated in combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer and as a single agent for the treatment of HER2-overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease.